|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
29,730,000 |
Market
Cap: |
1.43(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$26.52 - $75.32 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 20 |
Insider 3/6 Months : 20.6 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Gemeni Therapeutics is a clinical-stage precision medicine company developing therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). Co.'s lead product candidate, GEM103, is a recombinant form of the human complement factor H protein and is designed to address complement hyperactivity and overall dysregulation caused by loss of function mutations thus restoring retinal health in patients with AMD.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
388,891 |
388,891 |
1,041,066 |
Total Buy Value |
$0 |
$14,000,076 |
$14,000,076 |
$29,000,101 |
Total People Bought |
0 |
3 |
3 |
4 |
Total Buy Transactions |
0 |
3 |
3 |
6 |
Total Shares Sold |
5,359 |
10,077 |
1,816,761 |
3,929,683 |
Total Sell Value |
$262,142 |
$419,912 |
$108,633,360 |
$210,494,186 |
Total People Sold |
2 |
2 |
9 |
13 |
Total Sell Transactions |
5 |
8 |
40 |
59 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ashiya Mona |
Director |
|
2023-12-14 |
4 |
S |
$56.75 |
$24,584,100 |
I/I |
(433,200) |
224,405 |
|
53% |
|
Orbimed Genesis Gp Llc |
Director |
|
2023-12-14 |
4 |
S |
$56.75 |
$24,584,100 |
I/I |
(433,200) |
224,405 |
|
53% |
|
Bitterman Kevin |
Director |
|
2023-12-14 |
4 |
S |
$58.27 |
$1,197,567 |
I/I |
(20,549) |
806,160 |
|
53% |
|
Atlas Venture Associates Opportunity I, Llc |
10% Owner |
|
2023-12-14 |
4 |
S |
$58.27 |
$1,197,567 |
I/I |
(20,549) |
806,160 |
|
53% |
|
Atlas Venture Associates Opportunity I, Llc |
10% Owner |
|
2023-12-14 |
4 |
S |
$58.27 |
$1,796,437 |
D/D |
(30,825) |
1,479,686 |
|
53% |
|
Orbimed Genesis Gp Llc |
Director |
|
2023-12-14 |
4 |
S |
$57.73 |
$11,546 |
I/I |
(200) |
727,807 |
|
53% |
|
Ashiya Mona |
Director |
|
2023-12-14 |
4 |
S |
$57.73 |
$11,546 |
I/I |
(200) |
727,807 |
|
53% |
|
Bitterman Kevin |
Director |
|
2023-12-13 |
4 |
S |
$59.99 |
$212,865 |
I/I |
(3,548) |
826,709 |
|
55% |
|
Atlas Venture Associates Opportunity I, Llc |
10% Owner |
|
2023-12-13 |
4 |
S |
$59.99 |
$212,865 |
I/I |
(3,548) |
826,709 |
|
55% |
|
Atlas Venture Associates Opportunity I, Llc |
10% Owner |
|
2023-12-13 |
4 |
S |
$59.99 |
$319,357 |
D/D |
(5,323) |
1,510,511 |
|
55% |
|
Orbimed Genesis Gp Llc |
Director |
|
2023-12-13 |
4 |
S |
$58.56 |
$6,248,352 |
I/I |
(106,700) |
281,505 |
|
55% |
|
Ashiya Mona |
Director |
|
2023-12-13 |
4 |
S |
$58.56 |
$6,248,352 |
I/I |
(106,700) |
281,505 |
|
55% |
|
Bitterman Kevin |
Director |
|
2023-12-12 |
4 |
S |
$59.87 |
$3,263,328 |
I/I |
(51,967) |
830,257 |
|
54% |
|
Bryce Joanne |
Chief Financial Officer |
|
2023-12-12 |
4 |
AS |
$65.22 |
$163,062 |
D/D |
(2,500) |
2,500 |
|
-54% |
|
Bryce Joanne |
Chief Financial Officer |
|
2023-12-12 |
4 |
OE |
$2.65 |
$6,625 |
D/D |
2,500 |
5,000 |
|
- |
|
White William Richard |
|
|
2023-12-12 |
4 |
S |
$59.44 |
$2,118,239 |
D/D |
(33,511) |
0 |
|
54% |
|
White William Richard |
|
|
2023-12-12 |
4 |
OE |
$2.65 |
$203,883 |
D/D |
33,511 |
33,511 |
|
- |
|
Atlas Venture Associates Opportunity I, Llc |
10% Owner |
|
2023-12-12 |
4 |
S |
$59.87 |
$3,263,328 |
I/I |
(51,967) |
830,257 |
|
54% |
|
Atlas Venture Associates Opportunity I, Llc |
10% Owner |
|
2023-12-12 |
4 |
S |
$59.87 |
$4,895,032 |
D/D |
(77,951) |
1,515,834 |
|
54% |
|
Orbimed Genesis Gp Llc |
Director |
|
2023-12-12 |
4 |
S |
$60.16 |
$1,642,368 |
I/I |
(27,300) |
295,605 |
|
54% |
|
Ashiya Mona |
Director |
|
2023-12-12 |
4 |
S |
$60.16 |
$1,642,368 |
I/I |
(27,300) |
295,605 |
|
54% |
|
Bryce Joanne |
Chief Financial Officer |
|
2023-12-05 |
4 |
AS |
$55.29 |
$142,299 |
D/D |
(2,541) |
2,500 |
|
-47% |
|
Bryce Joanne |
Chief Financial Officer |
|
2023-12-05 |
4 |
OE |
$1.01 |
$1,294 |
D/D |
1,281 |
5,041 |
|
- |
|
Khara Rahul |
General Counsel |
|
2023-11-22 |
4 |
AS |
$50.34 |
$517,333 |
D/D |
(10,000) |
0 |
|
-43% |
|
Khara Rahul |
General Counsel |
|
2023-11-22 |
4 |
OE |
$14.69 |
$146,900 |
D/D |
10,000 |
10,000 |
|
- |
|
117 Records found
|
|
Page 2 of 5 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|